Oncimmune

Oncimmune's mission is to improve the understanding of the immune system to enable earlier disease detection and support the development of better, safer, and more targeted treatments. The company has strategically transitioned from developing its own diagnostic tests to offering its proprietary ImmunoINSIGHTS™ platform as a service to the life science industry. This partnership-led model allows it to generate revenue by providing deep biomarker insights to drug developers, helping to de-risk and optimize clinical programs, particularly in complex areas like cancer immunotherapy.

ImmunoINSIGHTS™ is a comprehensive analytical platform for antibody/autoantibody biomarker discovery, leveraging one of the world's largest antigen libraries (>9,000 antigens), Luminex xMAP® multiplex technology, and proprietary machine learning algorithms to profile the B-cell repertoire from minimal sample volumes.

Oncimmune competes with large CROs offering broad biomarker services and specialized proteomics companies like Olink. Its primary competitive moats are its massive proprietary antigen library and dedicated autoantibody bioinformatics, which provide deep, specialized insights into the humoral immune response for drug developers.